Close
Nordic 9Nordic 9

Global BioAccess Fund (investor - Venture Capital)

United States globalbioaccess.com
See something wrong or missing? Let us know
Offices:New York
Average round investment:48.1M USD
Average number per year:1.0
Distribution: 2023 (1)
Portfolio companies: Denmark Acesion Pharma
Mostly invests in: Denmark Denmark (1) Biotech (1)

1 tracked investments in:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Investors with similar profile to Global BioAccess Fund

Name Criteria
Belgium VIB
82%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: Denmark
  • Average number of deals per year: 1.3
  • Active last 12 months: Yes
Switzerland Roche Venture Fund
82%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: Denmark
  • Average number of deals per year: 1.5
  • Active last 12 months: Yes
Denmark Sunstone Life Science Ventures
82%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: Denmark
  • Average number of deals per year: 1.7
  • Active last 12 months: Yes
Denmark Lundbeckfond Ventures
81%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: Denmark
  • Average number of deals per year: 1.8
  • Active last 12 months: Yes
Denmark PKA
80%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: Denmark
  • Average number of deals per year: 1.5
  • Active last 12 months: Yes
Hong Kong CR-CP Life Science Fund
80%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Sweden Recipharm Venture Fund
80%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United Kingdom Rosetta Capital
80%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Germany Evotec AG
80%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Japan Kyoritsu Holdings
80%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Top